Chicagoland Peptides

Chicagoland Peptides products are Research Use Only ("RUO") and are intended solely for basic research, pharmaceutical research, laboratory experimentation, or the development of new tests — not for diagnosing, treating, curing, or preventing any disease or condition in any patient. These statements have not been evaluated by the U.S. Food and Drug Administration.

BPC-157 in Vitro: What Cell-Based and Isolated-Tissue Studies Report

Last reviewed: September 16, 2026

The pentadecapeptide BPC-157 (sequence GEPPPGKPADDAGLV) has been examined across a range of cultured-cell and isolated-tissue systems, and the in vitro literature is distinct from the much larger rodent literature in what it can and cannot show [1][2]. This guide summarises only what was observed in cell-based or isolated-tissue preparations, and names the model in each case. In tendon-derived systems, cultured rat Achilles tendon fibroblasts exposed to BPC-157 showed no direct change in proliferation by MTT assay, but explant outgrowth was accelerated, cell survival under hydrogen peroxide stress was increased, and transwell migration and cell spreading increased with concentration; FITC-phalloidin staining showed induced F-actin formation, and Western blotting showed increased phosphorylation of FAK and paxillin without change in total protein [1]. A separate report using cultured tendocytes found that BPC-157 alone did not alter growth of the cultured cells, but opposed the growth-inhibiting effect of 4-hydroxynonenal in both serum-containing and serum-deprived conditions, alongside in vivo tendon transection work in rats [2]. Angiogenesis-related in vitro results are not uniform. One study correlating cell culture with crushed and transected rat muscle and tendon reported no direct angiogenic effect of BPC-157 on cell cultures, while immunohistochemistry in the animal arm showed modulated VEGF, CD34 and FVIII staining [3]. Other work in human vascular endothelial cells reported increased VEGFR2 mRNA and protein without a change in VEGF-A, promotion of VEGFR2 internalisation that was blocked by the endocytosis inhibitor dynasore, time-dependent activation of the VEGFR2–Akt–eNOS pathway, and increased endothelial tube formation that dynasore also suppressed [4]. In human umbilical vein endothelial cells, BPC-157 was reported to increase proliferation by MTT and cell cycle analysis, increase migration in transwell and scratch assays, upregulate VEGF-a, accelerate tube formation, and alter phosphorylation of ERK1/2 and the downstream targets c-Fos, c-Jun and Egr-1, in a study whose in vivo arm used an alkali-burn rat model [5]. In isolated rat aorta, a concentration-dependent vasodilation was reported that was attenuated when the endothelium was removed and inhibited by L-NAME or haemoglobin; no direct relaxation was seen in a three-dimensional construct made of vascular smooth muscle cells [6]. The same work reported nitric oxide generation detected by intracellular labelling, increased phosphorylation of Src, caveolin-1 and eNOS that was abolished by a Src inhibitor, and reduced Cav-1–eNOS binding on co-immunoprecipitation [6]. An earlier study using rat gastric mucosal tissue homogenates reported that BPC-157 induced nitric oxide generation comparable to L-arginine, that this was not inhibited by L-NAME even at a tenfold higher concentration than that needed to block the L-arginine effect, and that NO synthesis was blunted when the peptide and L-arginine were combined [7]. A cluster of membrane-potential experiments used HEK293 cells. Bupivacaine-induced depolarisation was inhibited in the presence of BPC-157, in a study whose main arm was bupivacaine cardiotoxicity in rats [8]. Lidocaine-induced depolarisation of HEK293 cells was likewise counteracted, alongside rat work on local anaesthetic effects and the NO system [9]. Increasing magnesium concentration depolarised HEK293 cells, and this depolarisation was inhibited in the presence of BPC-157 [10]. Reviews of this electrolyte series describe HEK293 findings in which BPC-157 counteracted hyperkalaemia- and hypermagnesaemia-induced depolarisation and hypokalaemia-induced hyperpolarisation [11], and a review of antiarrhythmic cytoprotection frames these HEK293 results as membrane-level observations that sit alongside predominantly rodent in vivo models and limited human data [12]. In liver cell culture, rat clone 9 cells were used together with irradiated mice; BPC-157 was reported to decrease radiation-induced apoptosis, increase PCNA, promote KLF4 expression, and reduce lipid accumulation and HIF-2α expression, with siRNA knockdown of KLF4 abolishing these effects in the cells [13]. In an immunological in vitro assessment nested within a burn study in corticosteroid-treated mice, splenic cells from methylprednisolone-treated animals showed decreased reactivity relative to healthy controls, and addition of BPC-157 returned reactivity toward control values [14]; a related mouse study of CO2 laser injury referenced the same in vivo and in vitro healing framework [15]. In vitro metabolism has been characterised for analytical purposes. Plasma incubation experiments reported that BPC-157 forms a stable metabolite, and a weak cation exchange solid-phase extraction method was validated for urine detection [16]. A stable isotope labelling strategy with UHPLC-HRMS identified one metabolite from a novel pathway plus eight from conventional amide-bond cleavage across two in vitro incubation models, and a urine detection method for the parent peptide and five main metabolites was developed and validated [17]. Several narrative reviews place this in vitro material in context. A comparison with standard angiogenic growth factors noted that for tendon, muscle and bone, the growth-factor literature contains fewer in vitro studies than in vivo presentations, while BPC-157 was described as consistently applied across gastrointestinal and musculoskeletal injury models [18]. Two further review pieces by the same group describe BPC-157 as controlling angiogenesis and NO-system functions and report anti-tumour potential described in vivo and in vitro, together with corneal work in which neovascularisation was opposed rather than produced [19][20]. Taken together, the in vitro record for BPC-157 is heterogeneous by cell type and endpoint: migration, survival under oxidative stress and cytoskeletal signalling in fibroblasts [1], mixed findings on direct effects in endothelial and other cultures [3][4][5], endothelium-dependent responses in isolated vessel preparations [6], membrane-potential modulation in HEK293 cells [8][9][10], and analytically oriented metabolism work [16][17]. None of these are human clinical findings, and several of the cell-based results are reported as adjuncts to rodent experiments within the same papers [2][5][13].

In plain terms

Most of what is known about BPC-157 in the laboratory dish comes from a handful of cell types. In tendon cells grown in culture, the peptide did not make the cells divide faster, but the cells moved and spread more, survived better when stressed with hydrogen peroxide, and showed changes in two signalling proteins, FAK and paxillin [1]. In another culture study the peptide on its own did not change tendon cell growth, but it offset the growth-blocking effect of a chemical called 4-hydroxynonenal [2]. Results in blood-vessel cells are mixed. One group found no direct effect on cell cultures at all [3], while others reported more VEGFR2 receptor on human endothelial cells, more tube formation, and changes in Akt, eNOS and ERK1/2 signalling in cells [4][5]. In rings of rat aorta studied outside the body, relaxation depended on the vessel lining being intact and was blocked by nitric oxide inhibitors [6], and in rat stomach tissue homogenates the peptide generated nitric oxide in a way that L-NAME did not block [7]. A separate group of experiments used HEK293 cells to watch the electrical charge across the cell membrane. In those cell experiments the peptide offset the membrane changes caused by bupivacaine, lidocaine and high magnesium [8][9][10], and reviews summarise similar cell findings for high and low potassium [11][12]. In cultured rat liver cells exposed to radiation, the peptide was linked to less cell death and less fat build-up, and silencing the KLF4 gene removed those cell effects; mice were studied in the same paper [13]. Spleen cells taken from steroid-treated burned mice were also tested in culture [14][15]. Finally, laboratory metabolism work in plasma and incubation systems mapped the breakdown products of the peptide so they can be detected in urine for doping control [16][17]. Review articles put these dish-based results next to the larger animal literature [18][19][20]. All of the above is cell, tissue or animal work, not evidence from people.

Related products

References

  1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.. J Appl Physiol (1985). 2011. (in vitro) PubMed
  2. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zarkovic N, Borovic S, Srdjak M, Hajdarevic K, Kopljar M, Batelja L, Boban-Blagaic A, Turcic I, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.. J Orthop Res. 2003. (in vitro) PubMed
  3. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.. J Physiol Pharmacol. 2009. (in vitro) PubMed
  4. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.. J Mol Med (Berl). 2017. (in vitro) PubMed
  5. Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y, Zhang Y, Zhang W. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.. Drug Des Devel Ther. 2015. (in vitro) PubMed
  6. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway.. Sci Rep. 2020. (in vitro) PubMed
  7. Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, Turković B, Rotkvić I, Mise S, Zoricić I, Konjevoda P, Perović D, Jurina L, Separović J, Hanzevacki M, Artuković B, Bratulić M, Tisljar M, Gjurasin M, Miklić P, Stancić-Rokotov D, Slobodnjak Z, Jelovac N, Marović A. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure.. Eur J Pharmacol. 1997. (in vitro) PubMed
  8. Zivanovic-Posilovic G, Balenovic D, Barisic I, Strinic D, Stambolija V, Udovicic M, Uzun S, Drmic D, Vlainic J, Bencic ML, Sindic A, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 and bupivacaine.. Eur J Pharmacol. 2016. (in vitro) PubMed
  9. Lozic M, Stambolija V, Krezic I, Dugandzic A, Zivanovic-Posilovic G, Gojkovic S, Kovacevic J, Vrdoljak L, Mirkovic I, Kokot A, Petrovic A, Pavlov KH, Drmic D, Suran J, Blagaic AB, Seiwerth S, Sikiric P. In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro.. Emerg Med Int. 2020. (in vitro) PubMed
  10. Medvidovic-Grubisic M, Stambolija V, Kolenc D, Katancic J, Murselovic T, Plestina-Borjan I, Strbe S, Drmic D, Barisic I, Sindic A, Seiwerth S, Sikiric P. Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen.. Inflammopharmacology. 2017. (in vitro) PubMed
  11. Grubisic MM, Strbe S, Barisic I, Balenovic D, Stambolija V, Lozic M, Ostojic SB, Oreskovic I, Zizek H, Brcic K, Coric L, Staresinic M, Blagaic V, Oreskovic LB, Halle ZB, Matek D, Soldo D, Grizelj B, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.. Curr Neuropharmacol. 2026. (in vitro) PubMed
  12. Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Zivanovic Posilovic G, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Beketic Oreskovic L, Oreskovic I, Strbe S, Sikiric S, Tomic L, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias.. Pharmaceuticals (Basel). 2026. (in vitro) PubMed
  13. Huang BS, Huang SC, Chen FH, Chang Y, Mei HF, Huang HY, Chen WY, Pang JS. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro.. Life Sci. 2022. (in vitro) PubMed
  14. Sikiric P, Seiwerth S, Mise S, Staresinic M, Bedekovic V, Zarkovic N, Borovic S, Gjurasin M, Boban-Blagaic A, Batelja L, Rucman R, Anic T. Corticosteroid-impairment of healing and gastric pentadecapeptide BPC-157 creams in burned mice.. Burns. 2003. (animal) PubMed
  15. Bilic M, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice.. Burns. 2005. (animal) PubMed
  16. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.. Drug Test Anal. 2017. (in vitro) PubMed
  17. Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.. Molecules. 2023. (in vitro) PubMed
  18. Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH, Barisic I, Kokot A, Japjec M, Blagaic AB, Tvrdeic A, Rokotov DS, Vrcic H, Staresinic M, Sebecic B, Sikiric P. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.. Curr Pharm Des. 2018. (animal) PubMed
  19. Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.. Pharmaceuticals (Basel). 2025. (animal) PubMed
  20. Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.. Pharmaceuticals (Basel). 2025. (animal) PubMed